All Updates

All Updates

icon
Filter
M&A
Listing
BenevolentAI to go public via EUR 1.5 billion SPAC deal
AI Drug Discovery
Dec 6, 2021
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Dec 6, 2021

BenevolentAI to go public via EUR 1.5 billion SPAC deal

M&A
Listing

  • London-based AI drug discovery company BenevolentAI has entered into a merger agreement with Odyssey Acquisition, a European special purpose acquisition company (SPAC), to go public on the Euronext Amsterdam Stock Exchange (AEX). 

  • The deal, which is expected to close in Q1 2022, is reportedly the largest ever SPAC merger in Europe and it is expected to value the combined entity at EUR 1.5 billion (USD 1.7 billion). 

  • The deal will inject around EUR 390 million (USD 440 million) net proceeds into BenevolentAI, which will include EUR 300 million (USD 339 million) raised by Odyssey in its IPO earlier this year and EUR 135 million (USD 152 million) in private investment in public equity (PIPE) from its existing partners—AstraZeneca and Temasek—and other investors. The SPAC shareholders will receive a 23.5% stake, while PIPE investors will receive a 9.1% stake in the company.

  • The net proceeds of the transaction will be directed towards advancing the company’s AI platform and expanding its pipeline of over 20 drug candidates.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.